Download Files:
SR144528
SKU
HY-13439-10 mg
Category Reference compound
Tags Cannabinoid Receptor, GPCR/G Protein;Neuronal Signaling, Neurological Disease
$108 – $1,320
Products Details
Product Description
– SR144528 is a potent and selective CB2 receptor antagonist with a Ki of 0.6 nM.
Web ID
– HY-13439
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C29H34ClN3O
References
– [1]Rinaldi-Carmona M, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998 Feb;284(2):644-50.|[2]Thewke D, et al. AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors. Biochem Biophys Res Commun. 2009 Apr 3;381(2):181-6.|[3]Abalo R, et al. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil. 2010 Jun;22(6):694-e206.
CAS Number
– 192703-06-3
Molecular Weight
– 476.05
Compound Purity
– 99.86
SMILES
– O=C(C1=NN(CC2=CC=C(C)C=C2)C(C3=CC=C(Cl)C(C)=C3)=C1)N[C@H]4[C@@](C5)(C)CC[C@@]5([H])C4(C)C
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Cannabinoid Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.